All Stories

  1. Thrombin Generation and Atherothrombosis: What Does the Evidence Indicate?
  2. Sex hormone-binding globulin and thrombin generation in women using hormonal contraception
  3. Asthma is associated with enhanced thrombin formation and impaired fibrinolysis
  4. A reduction of prothrombin conversion by cardiac surgery with cardiopulmonary bypass shifts the haemostatic balance towards bleeding
  5. Simultaneous measurement of thrombin generation and fibrin formation in whole blood under flow conditions
  6. Thrombin Generation in Zebrafish Blood
  7. Low paediatric thrombin generation is caused by an attenuation of prothrombin conversion
  8. Differences in the mechanism of blood clot formation and nanostructure in infants and children compared with adults
  9. Effect of five therapeutic strategies on the coagulation defect induced by the thrombomodulin c.1611C>A mutation
  10. Thrombin Generating Capacity and Phenotypic Association in ABO Blood Groups
  11. Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombin generation
  12. Thrombin generation: biochemical possibilities and clinical reality
  13. The application of thrombin generation in real life clinical situations
  14. The balance of pro- and anticoagulant processes underlying thrombin generation
  15. Characterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation
  16. Global/integral assays in hemostasis diagnostics: promises, successes, problems and prospects
  17. Thrombin-dependent Incorporation of von Willebrand Factor into a Fibrin Network
  18. The effect of fibrin(ogen) on thrombin generation and decay
  19. Measurement of thrombin generation intra-operatively and its association with bleeding tendency after cardiac surgery
  20. Effect of Mieyou decoction on TLRs/NF-κB65 signal pathway in mice with Helicobacter pylori associated gastritis with splenogastric hygropyrexia syndrome
  21. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis
  22. Will One Size of Anticoagulant Dosage Fit All?
  23. Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article
  24. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: a rebuttal
  25. A new regulatory function of activated factor V: inhibition of the activation by tissue factor/factor VII(a) of factor X
  26. Data management in Thrombin Generation
  27. Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation
  28. Thrombin generation: What have we learned?
  29. Is there value in kinetic modeling of thrombin generation? No (unless…)
  30. Whole-Blood Thrombin Generation Monitored with a Calibrated Automated Thrombogram-Based Assay
  31. No Effect of Ethanol Intake on Thrombin Generation Parameters
  32. Cover Picture: Fluorogenic Peptide‐Based Substrates for Monitoring Thrombin Activity (ChemMedChem 4/2012)
  33. Fluorogenic Peptide‐Based Substrates for Monitoring Thrombin Activity
  34. Procoagulant effect of vitamin K antagonists?
  35. Increased thrombin generation among postmenopausal women using hormone therapy
  36. Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A
  37. Thrombin generation is extremely sensitive to preheating conditions
  38. Evaluation of the procoagulant activity in the plasma of cancer patients using a thrombin generation assay
  39. Monitoring new oral antithrombotics: what we should know before we can decide
  40. Monitoring platelet dependent thrombin generation in mice
  41. High Subretinal Fluid Procoagulant Activity in Rhegmatogenous Retinal Detachment
  42. The use of phosphorus oxychloride in the synthesis of amino acid p-nitroanilides
  43. The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by α2-macroglobulin-thrombin
  44. Thrombin Generation and Plasma DilutionThe Authors’ Reply
  45. Handbook of Hemophilia. Edited by K. M. Brinkhous and H. C. Hemker
  46. Determination of the Levels of Unfractionated and Low-Molecular-Weight Heparins in Plasma: Their Effect on Thrombin-Mediated Feedback Reactions in vivo
  47. Feedback Mechanisms in Coagulation
  48. Development of a Sensitive and Rapid Chromogenic Factor IX Assay for Clinical Use
  49. A Standard for Low Molecular Weight Heparin?
  50. Importance of Factor-IX-Dependent Prothrombinase Formation – The Josso Pathway – in Clotting Plasma
  51. IN MEMORY OF FRANÇOIS JOSSO
  52. A Double-blind Trial of Long-term Anticoagulant Treatment after Myocardial Infarction
  53. Spectrophotometric Method for the Assay of Human Blood Coagulation Factor VIII
  54. Role of Accessory Components in the Activation of Vitamin K-Dependent Coagulation Factors
  55. The Mechanism of Action of Oral Anticoagulants and Its Consequences for the Practice of Oral Anticoagulation
  56. The Inhibition of Platelet Prothrombinase Activity by Prostacyclin
  57. Half-Life Time and Control Frequency of Vitamin K-Dependent Coagulation Factors
  58. On the Clot-Promoting Activity of Human Platelets in a One-Stage Prothrombinase Assay
  59. Use of Chromogenic Peptide Substrates in the Determination of Clotting Factors II, VII, IX and X in Normal Plasma and in Plasma of Patients Treated with Oral Anticoagulants
  60. Clot-Promoting Effect of Platelet-Vessel Wall Interaction: Influence of Dietary Fats and Relation to Arterial Thrombus Formation in Rats
  61. Partial Purification of the Protein Moiety of Porcine Tissue Thromboplastin
  62. Different Properties of Factor VIII in Von Willebrand’s Disease with Respect to Recovery in Cryoprecipitate
  63. The technique of measuring thrombin generation with fluorescent substrates: 4. The H-transform, a mathematical procedure to obtain thrombin concentrations without external calibration
  64. The technique of measuring thrombin generation with fluorogenic substrates. 3: The effects of sample dilution
  65. The technique of measuring thrombin generation with fluorogenic substrates: 1. Necessity of adequate calibration
  66. Thrombin generation in whole blood
  67. Recollections on thrombin generation
  68. Recollections on thrombin generation
  69. Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths
  70. Thrombin-generating capacity in patients with von Willebrand's disease
  71. The contribution of ?2-macroglobulin thrombin to the endogenous thrombin potential
  72. The initiation phase – a review of old (clotting-) times
  73. Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis
  74. Caution in the interpretation of continuous thrombin generation assays: a rebuttal
  75. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk
  76. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system
  77. Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin
  78. Thrombin generation, a function test of the haemostaticthrombotic system
  79. Low Molecular Weight Activated Protein C Inhibitors as a Potential Treatment for Hemophilic Disorders
  80. The limits of simulation of the clotting system
  81. New approaches for measuring coagulation
  82. Age-dependency of thrombin generation
  83. Mathematical and biological models of blood coagulation. A rebuttal
  84. Fixed dosage of low‐molecular‐weight heparins causes large individual variation in coagulability, only partly correlated to body weight
  85. During coagulation, thrombin generation shifts from chemical to diffusional control
  86. Laboratory monitoring of low-molecular-weight heparin therapy—part II
  87. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B
  88. Good Mathematical Practice: Simulation of the Hemostatic-Thrombotic Mechanism, a Powerful Tool but One That Must Be Used with Circumspection
  89. Calibrated automated thrombinography (CAT)
  90. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time
  91. Thrombin generation assays: accruing clinical relevance
  92. Factor XI-Dependent Reciprocal Thrombin Generation Consolidates Blood Coagulation when Tissue Factor Is Not Available
  93. The love of the artist for his model of thrombin generation
  94. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics
  95. Fibrin polymerization is crucial for thrombin generation in platelet‐rich plasma in a VWF–GPIb‐dependent process, defective in Bernard–Soulier syndrome
  96. Phenotyping the haemostatic system by thrombography—potential for the estimation of thrombotic risk
  97. The Calibrated Automated Thrombogram (CAT): a universal routine test for hyper- and hypocoagulability
  98. Thrombinography can differentiate bleeding from nonbleeding patients with prolonged APTT
  99. Defective vWF-Fibrin-GPIb interaction causes impaired prothrombin consumption in Bernard-Soulier Syndrome
  100. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif—the C-domain
  101. von Willebrand factor stimulates thrombin-induced exposure of procoagulant phospholipids on the surface of fibrin-adherent platelets
  102. The ionic contrast medium ioxaglate interferes with thrombin-mediated feedback activation of factor V, factor VIII and platelets
  103. Calibrated Automated Thrombin Generation Measurement in Clotting Plasma
  104. Editorial
  105. Platelet procoagulant activities: the amplification loops between platelets and the plasmatic clotting system
  106. Pharmacokinetic and Pharmacodynamic Characterization of a Medium-Molecular-Weight Heparin in Comparison with UFH and LMWH
  107. Supramolecular Biology
  108. Critical perceptions on problem-based learning
  109. Regulation of Platelet Factor Va-dependent Thrombin Generation by Activated Protein C at the Surface of Collagen-adherent Platelets
  110. Inhibition of Tissue Factor-Factor VIIa-catalyzed Factor X Activation by Factor Xa-Tissue Factor Pathway Inhibitor: A ROTATING DISC STUDY ON THE EFFECT OF PHOSPHOLIPID MEMBRANE COMPOSITION
  111. Fundamental Mechanisms Implicated in Thrombosis: New Aspects
  112. Draculin, the anticoagulant factor in vampire bat saliva, is a tight-binding, noncompetitive inhibitor of activated factor X
  113. Heterogeneity in microparticle formation and exposure of anionic phospholipids at the plasma membrane of single adherent platelets
  114. Acquired APC resistance and oral contraceptives: differences between two functional tests
  115. Acquired APC resistance and oral contraceptives: differences between two functional tests
  116. Venous and Arterial Thrombosis: Pathophysiological and Clinical Aspects
  117. Antithrombotic drugs
  118. Fundamental Mechanisms Involved in Thrombosis and Haemostasis
  119. Endogenous thrombin potential
  120. Expression of biological activity of draculin, the anticoagulant factor from vampire bat saliva, is strictly dependent on the appropriate glycosylation of the native molecule
  121. Autocatalytic Peptide Bond Cleavages in Prothrombin and Meizothrombin
  122. Prevention of the Influence of Fibrin and α2-Macroglobulin in the Continuous Measurement of the Thrombin Potential
  123. Purification and Characterization of Multisquamase, the Prothrombin Activator Present in Echis Multisquamatus Venom
  124. The Ca2+‐Mobilizing Potency of α‐Thrombin and Thrombin‐Receptor‐Activating Peptide on Human Platelets
  125. Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor
  126. Human Factor Va1 and Factor Va2:  Properties in the Procoagulant and Anticoagulant Pathways
  127. Laboratory Assessment of Antithrombotic Therapy: What Tests and If So Why?
  128. Synthesis of peptide p‐nitroanilides mimicking fibrinogen‐ and hirudin‐binding to thrombin Design of slow reacting thrombin substrates
  129. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
  130. Can the Haemorrhagic Component of Heparin Be Identified? Or an Attempt at Clean Thinking on a Dirty Drug
  131. Prothrombin Contributes to the Assembly of the Factor Va-Factor Xa Complex at Phosphatidylserine-containing Phospholipid Membranes
  132. Inhibition of Prothrombinase at Macroscopic Lipid Membranes: Competition between Antithrombin and Prothrombin
  133. A convenient synthesis of amino acid p-nitroanilides; synthons in the synthesis of protease substrates
  134. Design and synthesis of thrombin substrates with modified kinetic parameters
  135. Production of thrombin as a probe for mixing of phospholipids in membranes on solid supports
  136. Prothrombin Activation by Prothrombinase in a Tubular Flow Reactor
  137. Analysis of thrombin generation in plasma
  138. An investigation of the coagulological potential of the venoms of some Central Asian snakes
  139. Monitoring of unbound protein in vesicle suspensions with off-null ellipsometry
  140. A generally applicable synthesis of amino acid p-nitroanilides as synthons
  141. Autoactivation of human blood coagulation factor XII on dextran derivatives of different molecular weight
  142. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C
  143. Ratios of anti‐factor Xa to antithrombin activities of heparins as determined in recalcified human plasma
  144. Feedback Mechanisms in Blood Coagulation and Their Inhibition by Heparins
  145. Surface exclusion and molecular mobility may explain Vroman effects in protein adsorption
  146. Simulation Model for Thrombin Generation in Plasma
  147. The Mechanisms of Thrombin Formation
  148. Elements from in vitro studies that help understand the action of heparins
  149. Procoagulant activities in venoms from central Asian snakes
  150. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
  151. Mode of Action of Annexin V (Vascular Anticoagulant Alpha), a Protein Synthesized by the Vessel Wall
  152. The determination of heparin in blood
  153. The mode of action of dermatan sulphate in plasma
  154. The anticoagulant mechanism of action of hirudin
  155. Annexin V (vascular anticoagulant alpha), an anticoagulant with a new mechanism of action
  156. Free factor Xa is on the main pathway of thrombin generation in clotting plasma
  157. Inhibition of phospholipid and platelet‐dependent prothrombinase activity in the plasma of patients with lupus anticoagulants
  158. The ex Vivo Correlate of the Antithrombotic Action of Heparin
  159. The prolongation of the thrombotest clotting time in newborns
  160. Adsorption kinetics of protein mixtures. A tentative explanation of “the vroman effect”
  161. Purification and characterization of a novel protein from bovine aorta that inhibits coagulation
  162. Adsorption Kinetics of Protein Mixtures A Tentative Explanation of the Vroman Effect
  163. Inhibition of factor XIa by antithrombin III
  164. The effect of factor Va on lipid dynamics in mixed phospholipid vesicles as detected by steady‐state and time‐resolved fluorescence depolarization of diphenylhexatriene
  165. The placental transport of [3H] vitamin K1 in rats
  166. Thrombin generation and inactivation in the presence of antithrombin III and heparin
  167. The activity state of factor VII in plasma: two pathways for the cold promoted activation of factor VII
  168. Chapter 10 Interplay between medicine and biochemistry
  169. Kinetics of thrombin-induced release and activation of platelet factor V
  170. Inhibition of Thrombin-Catalyzed Reactions in Blood Coagulation and Platelet Activation by Heparin Fractions in the Absence of Antithrombin III
  171. Preface
  172. Title Page
  173. Isolation and partial purification of a novel anticoagulant from arteries of human umbilical cord
  174. Vitamin K-dependent carboxylase: the carboxylation of exogenous substrates in different systems
  175. Effect of heparin and low molecular weight heparins on thrombin-induced blood platelet activation in the absence of antithrombin III
  176. Comparison between the effect of pentosan polysulphate heparin and antithrombin III injections in antithrombin III deficient patients
  177. Clotting factors secreted by monocytes and macrophages: Analytical considerations
  178. Measurement of Macrophage Cellular Procoagulant Activity
  179. The action of echis carinatus venom on the blood coagulation system. Demonstration of an activator of factor X
  180. Interaction of prothrombin with factor Va-phospholipid complexes
  181. Functional properties of factor Va subunits after proteolytic alterations by activated protein C
  182. On the procoagulant activity of platelets stimulated by collagen and thrombin
  183. Automated Determination of Heparin with Chromogenic Substrates
  184. Automated Spectrophotometric Heparin Assays
  185. Determination of Low Molecular Weight Heparin in Clinical Laboratory
  186. Heparin Neutralization during Collection and Processing of Blood Inhibited by Pyridoxal 5′-Phosphate
  187. Reevaluation of some properties of fibrinogen, purified from cord blood of normal newborns
  188. Factor VII, a Written Symposium
  189. Interaction of bovine blood clotting factor Va and its subunits with phospholipid vesicles
  190. Handbook of Synthetic Substrates
  191. Substrates
  192. Basic enzymology
  193. Determinations that can be carried out with chromogenic substrates
  194. Measuring the conversion of a chromogenic substrate
  195. Editorial Note reduction of infarct size: discrepancies between experimental work and clinical application
  196. Factor Va-factor Xa interaction. Effects of phospholipid vesicles of varying composition
  197. Heterogeneous biocatalysis in the generation of thrombin
  198. Interindividual variation in relationships between plasma heparin concentration and the results of five heparin assays
  199. Generation of Prothrombin‐Converting Activity and the Exposure of Phosphatidylserine at the Outer Surface of Platelets
  200. A comparison between vitamin K-dependent carboxylase from normal and warfarin-treated cows
  201. The inhibition of vitamin K-dependent carboxylase by cyanide
  202. Blood Cell Membranes and Haemostasis
  203. The Biochemistry of Blood Coagulation
  204. In vitro prothrombin synthesis from a purified precursor protein III. Preparation of an acid-soluble substrate for vitamin K-dependent carboxylase by limited proteolysis of bovine descarboxyprothrombin
  205. Partial purification of bovine liver vitamin K-dependent carboxylase by immunospecific adsorption onto antifactor X
  206. Thrombosis service in The Netherlands
  207. Inhibition of Activated Factors II, VII, IX, and X by Synthetic Organic Compounds Directed against the Active-Site Seryl Residue
  208. A New Method To Determine The Binding Of Factor X To Phospholipid Bilayers
  209. Temperature dependent transitions in several phospholipids measured by ellipsometry
  210. Contribution of the Platelet Factor V Content to Platelet Factor 3 Activity
  211. Advantages, Pitfalls, and Snags with Chromogenic Substrates
  212. ORAL TREATMENT OF HÆMOPHILIA A BY GASTROINTESTINAL ABSORPTION OF FACTOR VIII ENTRAPPED IN LIPOSOMES
  213. The Role of Phospholipids and Factor Va in the Mechanism of Prothrombin Activation
  214. Lipid Phase Transitions and Procoagulant Activity
  215. An inhibitor of clot formation in cord plasma
  216. A coagulation reagent completely devoid of factor X; Relation between clotting time and concentration of factor X
  217. The determination of prothrombin using synthetic chromogenic substrates; choice of a suitable activator
  218. A quick method for the determination of decarboxyfactor X
  219. Improvements of the method for the preparation of an artificial prothrombin reagent
  220. Activation of decarboxyfactor X by a protein from Russell's Viper venom
  221. In vitro prothombin sysnthesis from a purified precursor protein. II. Partial purification of bovine carboxylase
  222. Purification and properties of the phenprocoumon-induced decarboxyfactor X from bovine plasma
  223. The effect of γ-carboxyglutamate residues on the enzymatic properties of the activated blood clotting factor X
  224. The role of γ-carboxyglutamyl residues in the positive cooperative binding of Ca2+ to blood coagulation factor X
  225. The role of blood clotting factor V in the conversion of prothrombin and A decarboxy prothrombin into thrombin
  226. Computer evaluation of reference curves for the estimation of extrinsic coagulation factors
  227. Ellipsometry as a tool to study protein films at liquid-solid interfaces
  228. VITAMIN-K DEFICIENCY IN THE NEWBORN
  229. Paratopic interaction, a mechanism in the generation of structure bound enzymatic activity
  230. Reconstitution and lipid requirements of porcine tissue thromboplastin
  231. Heparin-like inhibitor of blood coagulation in normal newborn
  232. HEPARIN-LIKE INHIBITOR, NOT VITAMIN-K DEFICIENCY, IN THE NEWBORN
  233. A new method for the preparation of artificial factor II reagents from normal human and bovine plasma
  234. In vitro prothrombin synthesis from a purified precursor protein I. Development of a bovine liver cell-free system
  235. The influence of glycerol on the Ca flux in the isolated perfused rat heart
  236. Kinetics of the formation of the factor X activating enzyme of the blood coagulation system
  237. Quantitation of infarct size in man by means of plasma enzyme levels.
  238. Prothrombin and Related Coagulation Factors
  239. The Interaction between Prothrombin and Staphylocoagulase
  240. Activation of a pro-enzyme by a stoichiometric reaction with another protein
  241. Purification and properties of staphylocoagulase
  242. The influence of cadmium ions on the adsorption of prothrombin onto Al(OH)3 as a means to purify prothrombin
  243. Demonstration of three anomalous plasma proteins induced by a vitamin K antagonist
  244. Estimation of the rate constants in the michaelis-menten equations without restrictions as to time scale
  245. Inhibition of blood coagulation factors by serine esterase inhibitors
  246. Differential Interaction of Clotting Factors II, VII, IX and X with Sephadex and Dextran Blue
  247. Effects of Some Polyene Antibiotics on Human Platelets and their Function
  248. Different Cross-Over Electrophoretic Mobility of Factor Friuli X and Coumarin-induced Abnormal Factor X
  249. Theoretical considerations on a thermodynamic model of muscle action
  250. Quantitation in Cardiology
  251. Introduction
  252. Separation of blood coagulation factors II , VII, IX and X by cel filtration in the presence of Dextran blue
  253. CONTROL OF LONG-TERM ANTICOAGULANT TREATMENT
  254. Ischaemic Heart Disease
  255. General Kinetics of Enzyme Cascades
  256. Anticoagulants in Acute Myocardial Infarction
  257. Discussion
  258. Discussion
  259. Enzyme Kinetic Evaluation of Coagulation Systems
  260. Human Blood Coagulation
  261. Discussion
  262. The Thrombotest Dilution Curve and Its Diagnostic Significance
  263. Reaction Sequence of Blood Coagulation
  264. Formation of Prothrombin Converting Activity
  265. CRYOPRECIPITATES IN CLASSICAL HÆMOPHILIA
  266. Nature of Prothrombin Biosynthesis : Preprothrombinæmia in Vitamin K-deficiency
  267. Lipid solubility as a factor influencing the activity of uncoupling phenols
  268. A new application of the Clark oxygen electrode
  269. Dinitrophenol-induced ATPase of rat-liver mitochondria
  270. Inhibition of enzymes by Atebrin